(News Bulletin 247) – AB Science climbed nearly 6% on the Paris Stock Exchange on Tuesday following the publication in the journal ‘Alzheimer’s Research & Therapy’ of the positive results of its phase 3 study devoted to Alzheimer’s disease.
These results had shown that masitinib, the company’s lead molecule, could benefit patients by significantly slowing cognitive deterioration compared to placebo.
Unlike the majority of treatments in development for this indication, masitinib targets the brain’s innate immune system, including mast cells.
The results of this first phase 2B/3 study must now be confirmed by a confirmatory phase 3 trial, recently approved by the US Food and Drug Administration (FDA) and other agencies in Europe.
The study should recruit 600 patients, whose clinical diagnosis of mild or moderate Alzheimer’s disease has been confirmed.
Therapeutic options for patients with mild to moderate forms of Alzheimer’s disease are currently limited, as no disease-modifying therapies have been approved.
At 10:45 a.m., the AB Science share jumped 5.8% in expanded volumes while the Paris market fell by 0.4%.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
